Work

Abstract LB-412: Combining bexarotene with erlotinib in window of opportunity and phase II trials causes lung cancer responses independent of KRAS mutations

Year: 2011

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2011-lb-412

Authors: Konstantin H. Dragnev, Tian Ma, Jobin Cyrus, Fabrizio Galimberti, Vincent Memoli, Alexander M. Busch, Gregory J. Tsongalis, Marc A. Seltzer, David Johnstone, Cherie P. Erkmen, William Nugent, James R. Rigas, Xi Liu, Sarah J. Freemantle, Jonathan M. Kurie, Samuel Waxman, Ethan Dmitrovsky

Institutions: Dartmouth–Hitchcock Medical Center, Dartmouth College, Dartmouth Health, The University of Texas MD Anderson Cancer Center, Icahn School of Medicine at Mount Sinai

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1978461425

Cites:

Cited by:

Related to: 10